

Supplementary Information

The synthesis of heterosaccharides related to the fucoidan from *Chordaria flagelliformis* bearing L-fucofuranosyl unit


*Dmitry Z. Vinnitskiy, Vadim B. Krylov, Nadezhda E. Ustyuzhanina,
Andrey S. Dmitrenok, Nikolay E. Nifantiev*


Table of contents

Allyl 2- <i>O</i> - <i>p</i> -methoxybenzyl-3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (12)	4
2- <i>O</i> - <i>p</i> -methoxybenzyl-3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside trichloroacetimidates (13α)	7
2- <i>O</i> - <i>p</i> -methoxybenzyl-3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- β -L-fucopyranoside trichloroacetimidates (13β)	10
Allyl 2- <i>O</i> - <i>p</i> -methoxybenzyl-3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (5)	13
Methyl (allyl 2,3-di- <i>O</i> -benzyl-4- <i>O</i> - <i>tert</i> -butyldimethylsilyl β -D-glucopyranosyl)uronate (15)	16
Methyl (2,3-di- <i>O</i> -benzyl-4- <i>O</i> - <i>tert</i> -butyldimethylsilyl α,β -D-glucopyranosyl)uronate trichloroacetimidates (8)	19
Allyl 3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (16)	22
Allyl methyl 2,3,4-tri- <i>O</i> -benzyl- α,β -D-glucopyranosyluronate-(1 \rightarrow 2)-3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranosides (17)	25
Allyl methyl 2,3,4-tri- <i>O</i> -benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (18)	28
Allyl 2- <i>O</i> -benzyl-3,4-di- <i>O</i> -chloroacetyl- α -L-fucopyranosyl-(1 \rightarrow 3)-{methyl 2,3,4-tri- <i>O</i> -benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)}-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (19)	31
Sodium salt propyl α -L-fucopyranosyl-(1 \rightarrow 3)-{ α -D-glucopyranosyluronate-(1 \rightarrow 2)}- α -L-fucopyranosyl-(1 \rightarrow 3)- α -L-fucopyranoside (1)	34
Sodium salt propyl 3,4-di- <i>O</i> -sulfonato- α -L-fucopyranosyl-(1 \rightarrow 3)-{ α -D-glucopyranosyluronate-(1 \rightarrow 2)}-4- <i>O</i> -sulfonato- α -L-fucopyranosyl-(1 \rightarrow 3)-4- <i>O</i> -sulfonato- α -L-fucopyranoside (2)	37
Sodium salt allyl 2,4-di- <i>O</i> -sulfonato-3- <i>O</i> -benzyl- α -L-fucopyranoside (21)	40
2,3,5-tri- <i>O</i> -benzyl- β -L-fucofuranoside trichloroacetimidates (24)	42
Allyl 2,5-di- <i>O</i> -benzyl-3- <i>O</i> -benzoyl- α -L-fucofuranosyl-(1 \rightarrow 4)-methyl-2,3-di- <i>O</i> -benzyl- β -D-glucopyranosyl uronate (25α)	45
Allyl 2,3,5-tri- <i>O</i> -benzyl- α,β -L-fucofuranosyl-(1 \rightarrow 4)-methyl-2,3-di- <i>O</i> -benzyl- β -D-glucopyranosyl uronate (26)	51
Allyl methyl 2,3-di- <i>O</i> -benzyl-4- <i>O</i> - <i>tert</i> -butyldimethylsilyl- α,β -D-glucopyranosyluronate-(1 \rightarrow 2)-3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranosides (27)	54
Allyl methyl 2,3-di- <i>O</i> -benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)-3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (28)	57
Allyl methyl 2,5-di- <i>O</i> -benzyl-3- <i>O</i> -benzoyl- α -L-fucofuranosyl-(1 \rightarrow 4)-2,3-di- <i>O</i> -benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)-3- <i>O</i> -chloroacetyl-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (29)	60
Allyl 2,5-di- <i>O</i> -benzyl-3- <i>O</i> -benzoyl- α -L-fucofuranosyl-(1 \rightarrow 4)-methyl 2,3-di- <i>O</i> -benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (30)	63
Allyl 2- <i>O</i> -benzyl-3,4-di- <i>O</i> -chloroacetyl- α -L-fucopyranosyl-(1 \rightarrow 3)-{2,5-di- <i>O</i> -benzyl-3- <i>O</i> -benzoyl- α -L-fucofuranosyl-(1 \rightarrow 4)-methyl-2,3-di- <i>O</i> -benzyl- α -D-glucopyranosyluronate-	

(1→2)}-4- <i>O</i> -benzoyl- α -L-fucopyranosyl-(1→3)-2- <i>O</i> -benzyl-4- <i>O</i> -benzoyl- α -L-fucopyranoside (31)	66
Sodium salt proryl α -L-fucopyranosyl-(1→3)-{ α -L-fucofuranosyl-(1→4)- α -D-glucopyranosyluronate-(1→2)}- α -L-fucopyranosyl-(1→3)- α -L-fucopyranoside (3)	69
Sodium salt proryl 3,4-di- <i>O</i> -sulfonato- α -L-fucopyranosyl-(1→3)-{3- <i>O</i> -sulfonato- α -L-fucofuranosyl-(1→4)- α -D-glucopyranosyluronate-(1→2)}-4- <i>O</i> -sulfonato- α -L-fucopyranosyl-(1→3)-4- <i>O</i> -sulfonato- α -L-fucopyranoside (4)	72



Allyl 2-*O*-*p*-methoxybenzyl-3-*O*-chloroacetyl-4-*O*-benzoyl- α -L-fucopyranoside (12)






Acquisition Parameter


Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



2-*O*-*p*-methoxybenzyl-3-*O*-chloroacetyl-4-*O*-benzoyl- α -L-fucopyranoside trichloroacetimidates (13 α)



¹³C NMR (100.62 MHz), CDCl₃



133.50
129.83
129.47
129.36
128.58


113.84

94.57

77.32
77.00
76.68
72.59
71.99
71.80
71.25
67.54
60.34
55.24



40.59

21.00
16.10
14.18




Acquisition Parameter



Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



2-*O*-*p*-methoxybenzyl-3-*O*-chloroacetyl-4-*O*-benzoyl- β -L-fucopyranoside trichloroacetimidates (13 β)





¹³C NMR (100.62 MHz), CDCl₃





Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl 2-*O*-*p*-methoxybenzyl-3-*O*-chloroacetyl-4-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-*O*-benzyl-4-*O*-benzoyl- α -L-fucopyranoside (5)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Methyl (allyl 2,3-di-*O*-benzyl-4-*O*-*tert*-butyldimethylsilyl β -D-glucopyranosyl)uronate (15)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Methyl (2,3-di-*O*-benzyl-4-*O*-*tert*-butyldimethylsilyl α,β -D-glucopyranosyl)uronate trichloroacetimidates (8)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl 3-*O*-chloroacetyl-4-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-*O*-benzyl-4-*O*-benzoyl- α -L-fucopyranoside (16)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl methyl 2,3,4-tri-*O*-benzyl- α,β -D-glucopyranosyluronate-(1 \rightarrow 2)-3-*O*-chloroacetyl-4-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-*O*-benzyl-4-*O*-benzoyl- α -L-fucopyranosides (17)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl methyl 2,3,4-tri-*O*-benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)-4-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-*O*-benzyl-4-*O*-benzoyl- α -L-fucopyranoside (18)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl 2-*O*-benzyl-3,4-di-*O*-chloroacetyl- α -L-fucopyranosyl-(1 \rightarrow 3)-{methyl 2,3,4-tri-*O*-benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)}-4-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-*O*-benzyl-4-*O*-benzoyl- α -L-fucopyranoside (19)






Acquisition Parameter


Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z			Set Divert Valve	Waste



Sodium salt propyl α -L-fucopyranosyl-(1 \rightarrow 3)-{ α -D-glucopyranosyluronate-(1 \rightarrow 2)}- α -L-fucopyranosyl-(1 \rightarrow 3)- α -L-fucopyranoside (1)





¹³C NMR (150.92 MHz), D₂O




Acquisition Parameter


Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



Sodium salt propyl 3,4-di-*O*-sulfonato- α -L-fucopyranosyl-(1 \rightarrow 3)-{ α -D-glucopyranosyluronate-(1 \rightarrow 2)}-4-*O*-sulfonato- α -L-fucopyranosyl-(1 \rightarrow 3)- 4-*O*-sulfonato- α -L-fucopyranoside (2)





¹³C NMR (150.92 MHz), D₂O




Acquisition Parameter


Source Type	ESI	Ion Polarity	Negative	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	3200 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z			Set Divert Valve	Waste




Sodium salt allyl 2,4-di-O-sulfonato-3-O-benzyl- α -L-fucopyranoside (21)




¹³C NMR (150.92 MHz), D₂O, 303.0 K





2,3,5-tri-O-benzyl-β-L-fucofuranoside trichloroacetimidates (24)






Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



Allyl 2,5-di-O-benzyl-3-O-benzoyl- α -L-fucofuranosyl-(1 \rightarrow 4)-methyl-2,3-di-O-benzyl- β -D-glucopyranosyl uronate (25 α)





¹³C NMR (150.92 MHz), CDCl₃

169.23
165.41
138.53
137.72
133.74
133.21
129.73
128.38
128.31
128.27
128.17
128.11
127.67
127.64
127.55
127.51
127.23
117.58

102.58
100.94
83.51
82.89
81.84
81.81
77.21
77.06
77.00
76.79
76.36
75.45
75.25
74.79
74.25
72.05
71.58
70.36



52.61

15.49





Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl 2,5-di-O-benzyl-3-O-benzoyl- β -L-fucofuranosyl-(1 \rightarrow 4)-methyl-2,3-di-O-benzyl- β -D-glucopyranosyl uronate (25 β)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl 2,3,5-tri-O-benzyl- α,β -L-fucofuranosyl-(1 \rightarrow 4)-methyl-2,3-di-O-benzyl- β -D-glucopyranosyl uronate (26)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl methyl 2,3-di-*O*-benzyl-4-*O*-*tert*-butyldimethylsilyl- α,β -D-glucopyranosyluronate-(1 \rightarrow 2)-3-*O*-chloroacetyl-4-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-*O*-benzyl-4-*O*-benzoyl- α -L-fucopyranosides (27)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl methyl 2,3-di-O-benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)-3-O-chloroacetyl-4-O-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-O-benzyl-4-O-benzoyl- α -L-fucopyranoside (28)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl methyl 2,5-di-*O*-benzyl-3-*O*-benzoyl- α -L-fucofuranosyl-(1 \rightarrow 4)-2,3-di-*O*-benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)-3-*O*-chloroacetyl-4-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-*O*-benzyl-4-*O*-benzoyl- α -L-fucopyranoside (29)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl 2,5-di-O-benzyl-3-O-benzoyl- α -L-fucofuranosyl-(1 \rightarrow 4)-methyl 2,3-di-O-benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)-4-O-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-O-benzyl-4-O-benzoyl- α -L-fucopyranoside (30)







Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste





Allyl 2-*O*-benzyl-3,4-di-*O*-chloroacetyl- α -L-fucopyranosyl-(1 \rightarrow 3)-{2,5-di-*O*-benzyl-3-*O*-benzoyl- α -L-fucofuranosyl-(1 \rightarrow 4)-methyl-2,3-di-*O*-benzyl- α -D-glucopyranosyluronate-(1 \rightarrow 2)}-4-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2-*O*-benzyl-4-*O*-benzoyl- α -L-fucopyranoside (31)






Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z			Set Divert Valve	Waste





Sodium salt proryl α -L-fucopyranosyl-(1 \rightarrow 3)-{ α -L-fucofuranosyl-(1 \rightarrow 4)- α -D-glucopyranosyluronate-(1 \rightarrow 2)}- α -L-fucopyranosyl-(1 \rightarrow 3)- α -L-fucopyranoside (3)





178.56
13C NMR (125.77 MHz), CDCl₃

105.06
102.34
101.14
97.15
96.20
87.89
83.37
79.27
77.48
77.01
75.59
74.92
74.81
74.67
74.03
73.71
72.97
72.48
70.81
70.04
69.99
69.90
69.40
69.30
69.17
25.04
21.43
18.41
18.21
12.82




Acquisition Parameter


Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



Sodium salt proryl 3,4-di-*O*-sulfonato- α -L-fucopyranosyl-(1 \rightarrow 3)-{3-*O*-sulfonato- α -L-fucofuranosyl-(1 \rightarrow 4)- α -D-glucopyranosylurionate-(1 \rightarrow 2)}-4-*O*-sulfonato- α -L-fucopyranosyl-(1 \rightarrow 3)-4-*O*-sulfonato- α -L-fucopyranoside (4)



¹³C NMR (150.92 MHz), D₂O



Acquisition Parameter

Source Type	ESI	Ion Polarity	Negative	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	3200 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z			Set Divert Valve	Waste

